Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint - Business Wire (press release)

Phase 3 RESPONSE-2 Study of Jakafi® (ruxolitinib) Meets Primary Endpoint Business Wire (press release) WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announces the Phase 3 RESPONSE-2 study of Jakafi® (ruxolitinib) met its primary endpoint. Treatment with Jakafi achieved hematocrit control without the need for phlebotomy in ... Two Phase 3 Studies Reinforce Sustained Benefits of Treatment with Jakafi ...Equities.com all 2 news articles »

from phlebotomy - Google News http://bit.ly/1PIqoKX